Download PDF
CC BY-NC-ND 4.0 · Rev Bras Ortop (Sao Paulo) 2020; 55(05): 543-550
DOI: 10.1016/j.rboe.2017.12.008
Artigo Original
Joelho

Efeito do ácido zoledrônico e do alendronato no edema ósseo e dor na osteonecrose espontânea do joelho: Um novo paradigma no manejo[*]

Article in several languages: português | English
Sanjay Agarwala 
1   Hinduja Hospital and Medical Research Centre, Mumbai, India
,
Lokesh Sharoff
1   Hinduja Hospital and Medical Research Centre, Mumbai, India
,
Naeem Jagani
1   Hinduja Hospital and Medical Research Centre, Mumbai, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Resumo

Objetivo Determinar o efeito do tratamento combinado de ácido zoledrônico e alendronato no edema ósseo e na dor no joelho em casos de osteonecrose espontânea do joelho. A experiência dos autores com este tratamento é relatada.

Métodos Série de casos retrospectiva, incluindo 11 pacientes com osteonecrose espontânea do joelho confirmada por ressonância magnética. Os pacientes foram tratados com uma dose intravenosa única de 5 mg de ácido zoledrônico combinada com 35 mg de alendronato oral, 2 vezes por semana, por 16 semanas. Os escores da escala visual analógica foram aferidos antes do começo do tratamento, em 8 semanas e em 16 semanas de acompanhamento. O tamanho do edema da medula óssea adjacente à lesão foi medido em imagens de ressonância magnética coronal ponderadas em T2 no início do tratamento e em 16 semanas.

Resultados O escore médio da escala visual analógica em 0 semanas foi de 7,72, contra 0,81 em 16 semanas de tratamento, uma diferença estatisticamente significativa (p = 0,03). O envolvimento médio da medula óssea em 0 semanas foi de 80%, e foi reduzido para 11,81% em 16 semanas de tratamento, uma diferença também estatisticamente significativa (p = 0,03).

Conclusão Os dados mostram que a terapia combinada proporciona alívio da dor inicial e redução do edema ósseo, sendo segura, eficaz e bem tolerada em uma enfermidade dolorosa como a osteonecrose espontânea do joelho.

Palavras-chave

necrose - bisfosfonatos - osteoartrite - articulação do joelho

* Estudo realizado no Hinduja Hospital and Medical Research Centre, Mumbai, Índia. Publicado Originalmente por Elsevier Editora Ltda.




Publication History

Received: 30 July 2017

Accepted: 07 December 2017

Article published online:
19 December 2019

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Sociedade Brasileira de Ortopedia e Traumatologia. Published by Thieme Revnter Publicações Ltda
Rio de Janeiro, Brazil

 

  • Referências

  • 1 Ahlbäck S, Bauer GC, Bohne WH. Spontaneous osteonecrosis of the knee. Arthritis Rheum 1968; 11 (06) 705-733
    CrossrefPubMedGoogle Scholar
  • 2 Juréus J, Lindstrand A, Geijer M, Robertsson O, Tägil M. The natural course of spontaneous osteonecrosis of the knee (SPONK): a 1- to 27-year follow-up of 40 patients. Acta Orthop 2013; 84 (04) 410-414
    CrossrefPubMedGoogle Scholar
  • 3 Kraenzlin ME, Graf C, Meier C, Kraenzlin C, Friedrich NF. Possible beneficial effect of bisphosphonates in osteonecrosis of the knee. Knee Surg Sports Traumatol Arthrosc 2010; 18 (12) 1638-1644
    CrossrefPubMedGoogle Scholar
  • 4 Yamamoto T, Bullough PG. Spontaneous osteonecrosis of the knee: the result of subchondral insufficiency fracture. J Bone Joint Surg Am 2000; 82 (06) 858-866
    CrossrefPubMedGoogle Scholar
  • 5 Choy WS, Kim KJ, Lee SK, Yang DS, Kim CM, Park JS. Medial unicompartmental knee arthroplasty in patients with spontaneous osteonecrosis of the knee. Clin Orthop Surg 2011; 3 (04) 279-284
    CrossrefPubMedGoogle Scholar
  • 6 Mears SC, McCarthy EF, Jones LC, Hungerford DS, Mont MA. Characterization and pathological characteristics of spontaneous osteonecrosis of the knee. Iowa Orthop J 2009; 29: 38-42
    PubMedGoogle Scholar
  • 7 Aglietti P, Insall JN, Buzzi R, Deschamps G. Idiopathic osteonecrosis of the knee. Aetiology, prognosis and treatment. J Bone Joint Surg Br 1983; 65 (05) 588-597
    PubMedGoogle Scholar
  • 8 Son IJ, Kim MK, Kim JY, Kim JG. Osteonecrosis of the knee after arthroscopic partial meniscectomy. Knee Surg Relat Res 2013; 25 (03) 150-154
    CrossrefPubMedGoogle Scholar
  • 9 Houpt JB, Pritzker KP, Alpert B, Greyson ND, Gross AE. Natural history of spontaneous osteonecrosis of the knee (SONK): a review. Semin Arthritis Rheum 1983; 13 (02) 212-227
    CrossrefPubMedGoogle Scholar
  • 10 Karim AR, Cherian JJ, Jauregui JJ, Pierce T, Mont MA. Osteonecrosis of the knee: review. Ann Transl Med 2015; 3 (01) 6
    PubMedGoogle Scholar
  • 11 Reddy AS, Frederick RW. Evaluation of the intraosseous and extraosseous blood supply to the distal femoral condyles. Am J Sports Med 1998; 26 (03) 415-419
    PubMedGoogle Scholar
  • 12 Satku K, Kumar VP, Chong SM, Thambyah A. The natural history of spontaneous osteonecrosis of the medial tibial plateau. J Bone Joint Surg Br 2003; 85 (07) 983-988
    PubMedGoogle Scholar
  • 13 Lotke PA, Abend JA, Ecker ML. The treatment of osteonecrosis of the medial femoral condyle. Clin Orthop Relat Res 1982; (171) 109-116
    PubMedGoogle Scholar
  • 14 Agarwala S, Sule A, Pai BU, Joshi VR. Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford) 2002; 41 (03) 346-347
    CrossrefPubMedGoogle Scholar
  • 15 Agarwala S, Shah S, Joshi VR. The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years. J Bone Joint Surg Br 2009; 91 (08) 1013-1018
    PubMedGoogle Scholar
  • 16 Jureus J, Lindstrand A, Geijer M, Roberts D, Tägil M. Treatment of spontaneous osteonecrosis of the knee (SPONK) by a bisphosphonate. Acta Orthop 2012; 83 (05) 511-514
    CrossrefPubMedGoogle Scholar
  • 17 Meier C, Kraenzlin C, Friederich NF. et al. Effect of ibandronate on spontaneous osteonecrosis of the knee: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 2014; 25 (01) 359-366
    CrossrefPubMedGoogle Scholar
  • 18 Jäger M, Tillmann FP, Thornhill TS. et al. Rationale for prostaglandin I2 in bone marrow oedema--from theory to application. Arthritis Res Ther 2008; 10 (05) R120
    CrossrefPubMedGoogle Scholar
  • 19 Lecouvet FE, van de Berg BC, Maldague BE. et al. Early irreversible osteonecrosis versus transient lesions of the femoral condyles: prognostic value of subchondral bone and marrow changes on MR imaging. AJR Am J Roentgenol 1998; 170 (01) 71-77
    CrossrefPubMedGoogle Scholar
  • 20 Laslett LL, Doré DA, Quinn SJ. et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis 2012; 71 (08) 1322-1328
    CrossrefPubMedGoogle Scholar
  • 21 Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999; 36 (05) 315-328
    CrossrefPubMedGoogle Scholar
  • 22 Vallerand AH, Deglin JH, Sanoski CA. Davis's drug guide for nurses. 14th ed. Philadelphia: F.A. Davis Company; 2014
    Google Scholar
  • 23 Lewiecki EM. Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. Core Evid 2010; 4: 13-23
    PubMedGoogle Scholar
  • 24 Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007; 40 (05) 1238-1243
    CrossrefPubMedGoogle Scholar
  • 25 Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005; 10 (01) 52-62
    CrossrefPubMedGoogle Scholar
  • 26 Raynauld JP, Martel-Pelletier J, Berthiaume MJ. et al. Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period. Ann Rheum Dis 2008; 67 (05) 683-688
    PubMedGoogle Scholar
  • 27 Nishii T, Sugano N, Miki H, Hashimoto J, Yoshikawa H. Does alendronate prevent collapse in osteonecrosis of the femoral head?. Clin Orthop Relat Res 2006; 443 (443) 273-279
    CrossrefPubMedGoogle Scholar
  • 28 Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83 (09) 1032-1045
    CrossrefPubMedGoogle Scholar
  • 29 Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996; 97 (12) 2692-2696
    CrossrefPubMedGoogle Scholar